FDA approves Myqorzo for symptomatic obstructive hypertrophic cardiomyopathy

The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Approval of Myqorzo was granted to Cytokinetics.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup